Holen Sie sich die Stockscreener-App
0.351
3.54%
0.012
Handel nachbörslich:
.35
-0.001
-0.28%
IGC Pharma Inc Aktie (IGC) Neueste Nachrichten
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline - WSIL TV
IGC Pharma Reports 42% Revenue Growth, Advances Multiple Alzheimer's Drug Candidates | IGC Stock News - StockTitan
IGC (IGC Pharma) Price-to-Operating-Cash-Flow : (As of Nov. 14, 2024) - GuruFocus.com
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies - AccessWire
IGC Pharma CEO Reveals AI-Driven Strategy in Alzheimer's and Weight Loss Drug Development | IGC Stock News - StockTitan
IGC Pharma (STU:IGS1) Asset Turnover : 0.03 (As of Jun. 2024) - GuruFocus.com
MD’s IGC Pharma enrolls patients in Phase 2 trial for Alzheimer’s dementia drug - Maryland Daily Record
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 - AccessWire
Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts - Seeking Alpha
A Guide To The Risks Of Investing In IGC Pharma Inc (IGC) - Knox Daily
Investor’s Delight: IGC Pharma Inc (IGC) Closes Strong at 0.37, Up 0.13 - The Dwinnex
Was IGC Pharma Inc (IGC)’s session last reading good? - US Post News
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual Meeting - MSN
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge - Markets Insider
Financial Metrics Check: IGC Pharma Inc (IGC)’s Ratios for Trailing Twelve Months - The Dwinnex
A Look at IGC Pharma Inc (IGC) Shares in the Recent Past Indicates Growth - SETE News
IGC Pharma Inc’s latest rating changes from various analysts - Knox Daily
IGC’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Is IGC Pharma Inc (AMEX:IGC) stock a better investment at this time? - US Post News
AvePoint Inc’s latest rating changes from various analysts - Knox Daily
IGC Pharma Inc (AMEX: IGC) Down -0.99% This Year: What Is Going To Happen Next - Stocks Register
IGC Pharma director James Moran buys $200k in company stock - Investing.com Australia
IGC Pharma director James Moran buys $200k in company stock By Investing.com - Investing.com South Africa
Ipca Labs shares hit lifetime high after Nomura raises target price - Business Standard
IPCA Labs shares hit fresh 52-week high as Nomura upgrades target price on strong growth plans - Moneycontrol
Ipca Labs Shares Hit Life High As Nomura Hikes Target Price - NDTV Profit
Nomura expects IPCA Labs shares to rally over 20% from current price, retains Buy call - Business Upturn
EC approves Iqirvo plus UDCA to treat primary biliary cholangitis - World Pharmaceutical Frontiers
IPCA Laboratories Looking to Consolidate US Generics Business; Shares Gain - EquityPandit
Ipca Laboratories to Consolidate US Generics Business; Shares Up 1% - Indiainfoline
Ipca Laboratories to consider consolidaton of US generics business - CNBCTV18
StockNews.com Upgrades ICL Group (NYSE:ICL) to Strong-Buy - MarketBeat
Ipsen’s Iqirvo approved in Europe - The Pharma Letter
ICL Group (NYSE:ICL) Hits New 12-Month Low at $3.80 - MarketBeat
Ipsen’s Iqirvo® (elafibranor) approved in the European - GlobeNewswire
Ratio Revelations: IGC Pharma Inc (IGC)’s Financial Metrics in the Spotlight - The Dwinnex
IGC-AD1 shows promise in Alzheimer's tau pathology treatment By Investing.com - Investing.com Canada
Short Interest in ICL Group Ltd (NYSE:ICL) Declines By 6.3% - MarketBeat
IGM Biosciences (NASDAQ:IGMS) Trading Down 4.1% on Insider Selling - Defense World
ICL Group (NYSE:ICL) Shares Gap Down to $4.19 - Defense World
IGC-AD1 shows promise in Alzheimer's tau pathology treatment - Investing.com
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment - Business Wire
The Daily Hit: September 4, 2024 - Green Market Report
IGC Pharma targets Alzheimer’s market with anti-amyloid drug candidate - Green Market Report
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease - Yahoo Finance
IGC Pharma (NYSEMKT:IGC) Given New $3.75 Price Target at Ascendiant Capital Markets - Defense World
FTC Solar, Inc. (NASDAQ:FTCI) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
The Analyst Verdict: IGC Pharma In The Eyes Of 4 Experts - Benzinga
Moderna, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring - Barron's
The 7 Best Stocks Under 50 Cents To Buy For October 2024! - The Stock Dork
IGC Announces Results of its 2024 Annual Stockholders Meeting - Business Wire
IGC Pharma Inc [IGC] Is Currently -7.56 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
IGC Pharma’s IGC-1C shown to target tau protein and GLP-1 receptor - BioWorld Online
Stocks of IGC Pharma Inc (IGC) are poised to climb above their peers - SETE News
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease - Yahoo Finance
IGC Pharma identifies IGC-1A as potential GLP-1 agonist - BioWorld Online
IGC Pharma Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Ratios in Focus: Analyzing IGC Pharma Inc (IGC)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
IGC’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):